Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

Abstract: Embodiments include exerciser device placement in the development of an integrated circuit. Aspects of the invention include obtaining a design of an integrated circuit and creating a dynamic power blockage map for the integrated circuit. Aspects also include updating the integrated circuit design by placing one or more exercisers on the integrated circuit, wherein a location of the one or more exercisers on the integrated circuit is based on at least in part on the dynamic power blockage map. Based on a determination that the updated integrated circuit design complies with one or more design constraints, aspects further include outputting the updated integrated circuit design.

Abstract: The invention relates to a process for reducing the concentration of a fluorinated alkyne impurity, such as 3,3,3-trifluoropropyne (TFPY), in 2,3,3,3-tetrafluoropropene (HFO-1234yf) which comprises contacting such a mixture with a caustic material, such as sodium hydroxide (NaOH), under conditions effective to reduce the concentration of the fluorinated alkyne impurity, including in some practices reducing the concentration by at least about 50%.

Abstract: A computer-implemented method, the method being performed in a computerized system incorporating a central processing unit, a localization signal receiver, a display and a memory, the computer-implemented method involving: receiving a request from a user for a content; receiving at least one localization signal using the localization signal receiver; determining a location based on the received localization signal; using a plurality of content access rules to determine whether the requested content is authorized to be accessed from the determined location; and providing content to the user only if the content is authorized to be accessed from the determined location.

Abstract: The invention relates to a process for reducing the concentration of a fluorinated alkyne impurity, such as 3,3,3-trifluoropropyne (TFPY), in 2,3,3,3-tetrafluoropropene (HFO-1234yf) which comprises contacting such a mixture with a caustic material, such as sodium hydroxide (NaOH), under conditions effective to reduce the concentration of the fluorinated alkyne impurity, including in some practices reducing the concentration by at least about 50%.

Abstract: A computer-implemented method, the method being performed in a computerized system incorporating a central processing unit, a localization signal receiver, a display and a memory, the computer-implemented method involving: receiving a request from a user for a content; receiving at least one localization signal using the localization signal receiver; determining a location based on the received localization signal; using a plurality of content access rules to determine whether the requested content is authorized to be accessed from the determined location; and providing content to the user only if the content is authorized to be accessed from the determined location.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.